Document Detail

Effects of dextran sulfate on tracheal mucociliary velocity in dogs.
MedLine Citation:
PMID:  11010598     Owner:  NLM     Status:  MEDLINE    
We have shown that low molecular weight dextran, as a potential mucolytic agent, reduced the viscoelasticity and spinnability of cystic fibrosis (CF) sputum and improved its ciliary transportability in vitro; it also reduced viscoelasticity of healthy dog mucus in in vitro testing. In anesthetized dogs, dextran administered by aerosol at 65 mg/mL increased tracheal mucus velocity, but this increase was not sustained for higher concentrations. The purpose of the present study is to evaluate whether low mol. wt. dextran sulfate, a charged oligosaccharide, exhibits similar effects to previously tested neutral dextran when administered by aerosol to anesthetized dogs in terms of mucus rheology and mucociliary clearance rate. Healthy mongrel dogs were anesthetized with pentobarbital and intubated. Aerosols of Ringer's solution or dextran sulfate (m.w. 5000) dissolved in Ringer's were generated by Pari LC STAR nebulizer, and delivered during 30-min periods of spontaneous breathing. Tracheal transepithelial potential difference (PD, using agar filled electrodes) and tracheal mucociliary velocity (TMV, by charcoal marker particle transport) were measured under bronchoscopic control, and mucus for viscoelasticity analysis by magnetic rheometry was collected by the endotracheal tube method. We performed experiments in seven dogs, involving 30-min administrations of aerosol, separated by 30-min periods of no aerosol. All dogs received inhalations of 6.5 mg/mL, 20 mg/mL, and 65 mg/mL dextran sulfate. Tracheal mucus viscoelasticity (average log G* over 1-100 rad/s) decreased progressively with increasing dose of dextran sulfate; for the highest concentration (65 mg/mL), log G* decreased by a factor of 2.61 (p = 0.021). A modest increase in the TMV was observed for the first dose of dextran sulfate (128% of baseline at 6.5 mg/mL, p = 0.066); thereafter TMV was stable. PD increased significantly at each concentration of dextran sulfate compared with Ringer control; however, there was no additional change between the three groups. The solids content of collected airway fluid (%SC) was gradually increased during successive 30-min dextran sulfate aerosols, indicating a significant residence time for the dextran in the mucus, and correlating with the decrease in viscoelasticity. These results suggest that dextran sulfate may be potentially of therapeutic value as a mucolytic agent, assisting mucus clearance by cough and physiotherapy, although whether it stimulates mucociliary clearance remains to be proven.
E Sudo; W A Boyd; M King
Related Documents :
1048598 - Response of the regional lymphatic system of the sheep to acute stress and adrenaline.
23209948 - Certain red blood cell indices of maternal and umbilical cord blood in owerri, nigeria:...
3565608 - Thoracic duct lymph flow during head-out water immersion in conscious dogs.
11010598 - Effects of dextran sulfate on tracheal mucociliary velocity in dogs.
1111558 - Pulmonary blood flow distribution after banding of pulmonary artery.
18171328 - Quality of leucoreduced red blood cell concentrates: 5 years of follow-up in france.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine     Volume:  13     ISSN:  0894-2684     ISO Abbreviation:  J Aerosol Med     Publication Date:  2000  
Date Detail:
Created Date:  2000-09-21     Completed Date:  2000-09-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8809251     Medline TA:  J Aerosol Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  87-96     Citation Subset:  T    
Pulmonary Research Group, University of Alberta, Edmonton, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aerosols / administration & dosage
Analysis of Variance
Dextran Sulfate / administration & dosage,  pharmacology*
Indicators and Reagents / administration & dosage,  pharmacology*
Mucociliary Clearance / drug effects*
Mucus / secretion
Nebulizers and Vaporizers
Reg. No./Substance:
0/Aerosols; 0/Indicators and Reagents; 9042-14-2/Dextran Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regional mucociliary clearance in patients with cystic fibrosis.
Next Document:  Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient'...